Skip to main content
SpringerLink
Log in
Book cover

Applications of Pharmacokinetic Principles in Drug Development pp 333–372Cite as

Pharmacokinetic/Pharmacodynamic Modeling in Drug Development

  • Chapter

Abstract

Pharmacokinetic (PK) and pharmacodynamic (PD) modeling is employed to establish correlation of the concentration-time relationship (PK) with effect-concentration relationship (PD) in order to provide a better understanding of the time course of an effect (PK/PD) after administration of drug1,2,3,4.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Meibohm B, Derendorf H. Basic concepts of pharmacokinetic/pharmacodynamic (PK/PD) modelling. hit J Clin Pharmacol Ther 1997 Oct;35(10):401–13.

    CAS  Google Scholar 

  2. Derendorf H, Meibohm B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives. Pharm Res. 1999 Feb;16(2):176–85.

    Article  PubMed  CAS  Google Scholar 

  3. Gabrielsson J and Weiner D. Pharmacokinetic and pharmacodynamic data analysis: Concepts and applications. 3rd Edition., Apotekarsocieteten, Swedish pharmaceutical society, 2000.

    Google Scholar 

  4. Kwon Y. Handbook of essential pharmacokinetics, pharmacodynamics and drug metabolism for industrial scientists. Kluwer Academic/Plenum Publishers, New York, 2001.

    Google Scholar 

  5. Physician’s Desk Reference, (56), Medical Economics Company, Inc., Montvale, NJ 2002.

    Google Scholar 

  6. Lesko LJ, Rowland M, Peck CC, Blaschke TF. Optimizing the science of drug development: opportunities for better candidate selection and accelerated evaluation in humans. Pharm Res. 2000 Nov;17(11):1335–44. Review.

    Google Scholar 

  7. Hochhaus G, Barrett JS, Derendorf H. Evolution of pharmacokinetics and pharmacokinetic/dynamic correlations during the 20th century. J Clin Pharmacol. 2000 Sep;40(9):908–17.

    Article  PubMed  CAS  Google Scholar 

  8. Teorell T. Kinetics of distribution of substances administered to the body I. The extravascular modes of administration. Arch Int Pharmacodyn Ther 1937: 57: 202–225.

    Google Scholar 

  9. De Jongh SE, Wijnans M. The influence of divided doses of drugs on the duration of effect and integral of effect.Acta Physiol Pharmacol Neerl 1950: 1: 237–255.

    Google Scholar 

  10. Garrett ER, Thomas R, Wallach D, Always C. Psicofuranine: kinetics and mechanisms in vivo with the application of the analog computer. J Pharmac Exp Ther 1960: 140: 106–118.

    Google Scholar 

  11. Levy G. Kinetics of pharmacological effects. Clin Pharm Ther 1966: 7: 362–372.

    CAS  Google Scholar 

  12. Wagner JG. Kinetics of pharmacologic response. I. Proposed relationships between response and drug concentration in the intact animal and man J Theor Biol 1968: 20: 173–201.

    CAS  Google Scholar 

  13. Sheiner LB. Computer aided long-term anticoagulation therapy.Computer Biomed Res 1969: 10: 22–35.

    Google Scholar 

  14. Gibaldi M, Perrier D. Pharmacokinetics. New York: Marcel and Dekker, 1975.

    Google Scholar 

  15. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clinical Pharmacokinetics 1981: 6: 429–453.

    Article  PubMed  CAS  Google Scholar 

  16. Boudinot FD, D’Ambrosio R, Jusko WJ. Receptor-mediated pharmacodynamics of prednisolone in rat. Journal of Pharmacokinetics and Biopharmaceutics 1986: 14: 469–493.

    PubMed  CAS  Google Scholar 

  17. Peck CC, Barr WH, Benet LZ, Collins J, Desjardins RE, Frust DE, et al. Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Pharm Sci 1992: 81:605–610.

    Article  CAS  Google Scholar 

  18. Sheiner LB, Ludden TM. Population pharmacokinetics and pharmacodynamics. Annu Rev Pharmacol Toxicol 1992: 32: 185–209.

    Article  PubMed  CAS  Google Scholar 

  19. Derendorf H and Hochhaus G. Handbook of pharmacokinetic/pharmacodynamic correlation. CRC Press, Boca Raton, 1995.

    Google Scholar 

  20. Bruno R, Vivier N, Verginol J: A popuation pharmacokinetic model for Docetaxel (Taxotere): model building and validation. J Pharmacokinetic Biopharm 1996: 24; 153.

    Article  CAS  Google Scholar 

  21. US FDA Guidance for Industry. Population Pharmacokinetics (Issued 2/1999, Posted 2/10/1999).

    Google Scholar 

  22. US FDA Guidance for Industry. Exposure-Response Relationships: Study Design, Data Analysis, and Regulatory Applications. DRAFT GUIDANCE. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), March 2002.

    Google Scholar 

  23. Gibaldi M, Perrier D. Pharmacokinetics. 2nd edition, New York: Marcel Dekker, 1982.

    Google Scholar 

  24. Rowland M, Tozer TN. Clinical Pharmacokinetics, Concepts and Application (third edition), Williams and Wilkins, Baltimore, 1995.

    Google Scholar 

  25. Barrett JS. Population pharmacokinetics in Pharmacokinetics in drug discovery, Schoenwald RD eds., CRC Press, 2002.

    Google Scholar 

  26. Colburn WA. Optimizing the use of biomarkers, surrogate endpoints, and clinical endpoints for more efficient drug development. Journal of Clinical Pharmacology 2000: 40, 1419–1427.

    PubMed  CAS  Google Scholar 

  27. Meihbohm B., Derendorf H. Pharmacokinetic/pharmacodynamic studies in drug product development. Minireview. Journal of Pharmaceutical Sciences 2002; 18–31.

    Google Scholar 

  28. Chaikin P, Rhodes GR, Bruno R, Rohatagi S, Natarajan C. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective. J Clin Pharmacol. 2000 Dec;40(12 Pt 2):1428–38. Review.

    CAS  Google Scholar 

  29. CAST investigators (Cardiac Arrhythmia Suppression Trial Investigators): Preliminary report: effect of encainide and flecainide on mortality in a rondamized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989: 321: 406–412.

    Article  Google Scholar 

  30. The international Chronic Granulomatus Disease Cooperative Study Group: A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991: 324: 509526.

    Google Scholar 

  31. Reidenberg MM, Goodman H, Erle H, Gray G, Lorenzo B, Leipzig RM, Meyer BR, Drayer DE. Hydromorphone levels and pain control in patients with severe chronic pain. Clin Pharmacol Ther 1988: 44: 376.

    CAS  Google Scholar 

  32. Mawer GE, Ahmad R, Dobbs SM, Tooth JA.. Experience with a gentamicin nomogram. Postgrad Med J. 1974 Nov;50 Suppl 7:31–2.

    Google Scholar 

  33. Weaver ML, Tanzer JM, Kramer PA..Pilocarpine disposition and salivary flow responses following intravenous administration to dogs. Pharm Res. 1992 Aug;9(8):1064–9.

    Article  PubMed  CAS  Google Scholar 

  34. McDevitt DG, Shand DG. Plasma concentrations and the time-course of beta blockade due to propranolol. Clin Pharmacol Ther. 1975 Dec;18(06):708–13.

    PubMed  CAS  Google Scholar 

  35. Lalonde RL, Straka RJ, Pieper JA, Bottorff MB, Mirvis DM. Propranolol pharmacodynamic modeling using unbound and total concentrations in healthy volunteers. J Pharmacokinet Biopharm. 1987 Dec;15(6):569–82.

    Article  PubMed  CAS  Google Scholar 

  36. Dingemanse J, Van Bree JBMM and Danhof M. Pharmacokinetic modeling of anticonvulsant response of Phenobarbital in rats. J Pharmacol Exp Ther 1989: 249: 601.

    PubMed  CAS  Google Scholar 

  37. Schaefer HG, Heining R, Ahr G, Adelmann H, Tetzioff W, Kubimann J 1997. Pharmacokineticpharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for nisoldipine controlled-release dosage form. Eur J. Clin Pharmacol 51: 473–480.

    Article  PubMed  CAS  Google Scholar 

  38. Suri A, Grundy BL, Derendorf H. Pharmacokinetics and pharmacodynamics of enantiomers of ibuprofen and flurbiprofen after oral administration. Int J Clin Pharmacol Ther. 1997 Jan;35(1):1–8.

    PubMed  CAS  Google Scholar 

  39. Holford NHG, Sheiner LB. Understanding the dose-effect relationship: clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokinet. 1981; 6: 429–453.

    Article  PubMed  CAS  Google Scholar 

  40. Rohatagi S. PhD Thesis. Pharmacokinetic and Pharmacodynamic modelling of methylprednisolone and prednisolone after single and multiple administration, 1995.

    Google Scholar 

  41. Dalla Costa T, Nolting A, Rand K, Derendorf H. Pharmacokinetic-pharmacodynamic modelling of the in vitro antiinfective effect of piperacillin-tazobactam combinations. Int J Clin Pharmacol Ther. 1997 Oct;35(10):426–33.

    PubMed  Google Scholar 

  42. Jonkers RE, Braat MC, Koopmans RP, Van Boxtel CJ. Pharmacodynamic modelling of the drug-induced downiegulation of a beta 2-adrenoceptor mediated response and lack of restoration of receptor function after a single high dose of prednisone. Eur J Clin Pharmacol. 1995;49(1–2):37–44.

    Article  PubMed  CAS  Google Scholar 

  43. Van den Meiracker AH, Manint Veld, AJ, Boomsma F, Fishberg DJ Molinoff PB Schalekamp MADH. Hemodynamic and beta-adrenergic receptor adaptation during long-term beta-adrenoreceptor blockade. Circulation 1989: 80: 903.

    Article  PubMed  Google Scholar 

  44. Antal EJ, Pyne DA, Starz KE, Smith RB. Probability models in pharmacodynamic analysis of clinical trials, in Pharmacokinetics and pharmacodynamics. Vol 2, Currents problems, potential solutions, Kroboth PD, Smith RB, Juhl RP eds., Harvey Whitney Books, Cincinnati, 1988, 219.

    Google Scholar 

  45. Holford, N.H.G. and Sheiner, L.B., Kinetics of pharmacologic response., in Pharmacokinetics: Theory and Methodology, Rowland, M. and Tucker, G. Editors.,Pergamon Press, New York, 1985, 189–212.

    Google Scholar 

  46. Matthews JC. Fundamentals of receptor, enzyme and transport kinetics. CRC Press, Boca Raton, 1993.

    Google Scholar 

  47. Derendorf H, Hochhaus G, Mollmann H, Barth J, Krieg M, Tunn S, Mollmann C. Receptor-based pharmacokinetic-pharmacodynamic analysis of corticosteroids. J Clin Pharmacol. 1993 Feb;33(2):115–23.

    PubMed  CAS  Google Scholar 

  48. Shahin M, Iyengar SS, Rao RM. Computers in simulation and modeling of complex biological systems. CRC Press, Boca Raton, 1985.

    Google Scholar 

  49. Kac M. Some mathematical models in science. Science. 1969 Nov 7;166(906):695–9.

    Article  PubMed  CAS  Google Scholar 

  50. Holford NHG. Clinical pharmacokinetics and pharmacodynamics of warfarin: Understanding the dose-effect relationship. Clinical Pharmacokinetics 1986: 11: 483–504.

    Article  PubMed  CAS  Google Scholar 

  51. Mollmann H, Hochhaus G, Rohatagi S, Barth J, Derendorf H. Pharmacokinetic/pharmacodynamic evaluation of deflazacort in comparison to methylprednisolone and prednisolone. Pharm Res. 1995 Jul;12(7):1096–100.

    Article  PubMed  CAS  Google Scholar 

  52. Gisleskog PO, Hermann D, Hammarlund-Udenaes M Karlsson MO. Validation of a population pharmacokinetic/pharmacodynamic model for 5a-reductase inhibitors. Eur J Pharm Sci 1999: 8: 291–299.

    Article  Google Scholar 

  53. Gobburu JVS, Lawrence J. Application of resampling techniques to estimate exact significance levels for covariate selection during nonlinear mixed effects model building: Some inferences. Pharm Res 2002: 19(1): 92–98.

    Article  PubMed  CAS  Google Scholar 

  54. Rohatagi S, Bye A, Mackie AE and Derendorf H. Mathematical Modeling of Cortisol Circadian Rhythm and Cortisol Suppression. Eur. J. Pharm. Sci. 4: 341–350, 1996.

    Article  CAS  Google Scholar 

  55. Lalonde RL, O’Rear TL, Wainer IW, Drda KD, Herring VL, Bottorff MB. Labetalol pharmacokinetics and pharmacodynamics: evidence of stereoselective disposition. Clin Pharmacol Ther. 1990 Nov;48(5):509–19.

    Article  PubMed  CAS  Google Scholar 

  56. Zannikos PN, Rohatagi S, Jensen BK, DePhillips S, Massignon D, Calic F, Sibille M, Kirkesseli S. Pharmacokinetics, Pharmacodynamics and Safety of a Platelet GPIIb/IIIa Antagonist, RGD891, Following Intravenous Administration in Healthy Male Volunteers. J. Clin Pharmacol., 40: 1245–1256, 2000.

    PubMed  CAS  Google Scholar 

  57. Grabowski H, Vernon J, DiMasi JA. Returns on research and development for 1990s new drug introductions. Pharmacoeconomics 2002;20 Suppl 3:11–29.

    Article  PubMed  Google Scholar 

  58. DiMasi JA. The value of improving the productivity of the drug development process: faster times and better decisions. Pharmacoeconomics 2002;20 Suppl 3:1–10.

    Article  PubMed  Google Scholar 

  59. Peck CC, Barr WH, Benet, LZ, Collins D, R.E., Furst DE, Harter JG, Levy G, Ludden T, Rodman JH, Sanathanan L, Schentag JJ, Shah VP, Sheiner LB, Skelly JP, Stanski DR, Temple RJ, Vishwanathan CT, Weissinger J and Yacobi A. Opportunities for the integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development, Drug Development 1994: 34, 111–119.

    CAS  Google Scholar 

  60. Rolan PE, Mercer AJ, Wootton R, Posner J. Pharmacokinetics and pharmacodynamics of tucresol, an antisickling agent, in healthy volunteers. Br J Clin Pharmacol 1995: 39: 375–380.

    Article  PubMed  CAS  Google Scholar 

  61. Nades H, Muller TH, Weisenberger H, Guth B, Brickl R. Inhibition of platelet aggregation as a surrogate marker. J Clin Pharmacol 1997: 37: 59S–64S.

    Article  PubMed  Google Scholar 

  62. Barrett JS, Yu J, Kapil R, Padovani P, Brown F, Ebling WF, Corjay MH, Reilly TM, Bozarth JM, Mousa SA, Pieniaszek HJ Jr. Disposition and exposure of fibrogen receptor antagonist XV459 on alphallbeta3 binding sites in the guinea pig. Biopharm Drug Dispos 1999: 20: 309–318.

    Article  PubMed  CAS  Google Scholar 

  63. Benincosa U, Chow FS, Tobia LP, Kwok DC, Davis CB, Jusko WJ. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to faction IX in cynomolgus monkeys. J Pharmacol Exp Ther 2000: 292: 810–816.

    PubMed  CAS  Google Scholar 

  64. Gobburu JV, Tenhoor C, Rogge MC, Frazier DE Jr, Thomas D, Benjamin C, Hess DM, Jusko WJ. Pharmacokinetics/dynamics of 5c8, a monoclonal antibody to CD154 (CD40 ligand) suppression of an immune response in monkeys. J Pharmacol Exp Ther 1998: 286: 925–930.

    PubMed  CAS  Google Scholar 

  65. Van Der Graaf PH, Van Schaick EA, Math-ot RA, Ijzerman AP, Danhof M. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: Estimation of in vivo operational affinity and efficacy at adenosine Al receptors. J Pharmacol Exp Ther 1997: 283: 809–816.

    Google Scholar 

  66. Cox EH, Kerbusch T, Van der Graaf PH, Danhof M. Pharmacokinetic-pharmacodynamic modeling of electroencephalogram effect of synthetic opioids in rats: Correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 1998: 284: 1095–1103.

    PubMed  CAS  Google Scholar 

  67. Mandema JW, Tukker E, Danhof M. In vivo characterization of the pharmacodynamic interaction of a benzodiazepine agonist and antagonist: midazolam and flumazeni. J Pharmacol Exp Ther 1992: 260: 3644.

    Google Scholar 

  68. Barrett JS, Hochadel TJ, Morales RI, Rohatagi S, DeWitt KE, Watson SK, DiSanto AR. Pharmacokinetics and Safety of a Selegiline Transdermal System Relative to Single-Dose Oral Administration in the Elderly. Am J Ther. 1996 Oct;3(10):688–698.

    Article  PubMed  Google Scholar 

  69. Bauer JA, Balthasar JP, Fung HL. Application of pharmacodynamic modeling for designing time-variant dosing regimens to overcome nitroglycerine tolerance in experimental heart failure. Pharm Res 1997: 14: 1140–1145.

    Article  PubMed  CAS  Google Scholar 

  70. Khor SP, McCarthy K, Dupont M, Murray K, Timony G. Pharmacokinetics, pharmacodynamics, allometry and dose selection of rPSGL-Ig for Phase I trial. J. Pharmacol Exp Ther 293: 618–624.

    Google Scholar 

  71. Pechstein B, Nagaraja NV, Hermann R, Romeis P, Locher M, Derendorf H. Pharmacokineticpharmacodynamic modeling of testosterone and luteinizing hormone suppression by cetrorelix in healthy volunteers. J Clin Pharmacol. 2000 Mar;40(3):266–74.

    Article  PubMed  CAS  Google Scholar 

  72. Radwanski E, Chakraborty A, Van Wart S, Huhn RD, Cutler DL, Affrime MB, Jusko WJ. Pharmacokinetics and leukocyte responses of recombinant human interleukin-10. Pharm Res. 1998 Dec;15(12):1895–1901.

    Article  PubMed  CAS  Google Scholar 

  73. Schaefer HG, Heinig R, Ahr G, Adelmann H, Tetzloff W, Kuhlmann J. Pharmacokineticpharmacodynamic modeling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 1997: 51: 473–480.

    Article  PubMed  CAS  Google Scholar 

  74. Argenti D, Vaccaro SK, Shah B, Gillen, Rohatagi S, Jensen BK. Effect of food and gender on the pharmacokinetics of RP 73401, a phosphodiesterase IV inhibitor. Int J Clin Pharmacol Ther. 2000 Dec;38(12):588–94.

    PubMed  CAS  Google Scholar 

  75. Rohatagi S, Calic F, Harding N, Ozoux ML, Bouriot JP, Kirkesseli S, DeLeij L, Jensen BK. Pharmacokinetics, pharmacodynamics, and safety of inhaled cyclosporin A (ADI628) after single and repeated administration in healthy male and female subjects and asthmatic patients. J Clin Pharmacol. 2000 Nov;40(11):1211–26.

    PubMed  CAS  Google Scholar 

  76. Marino MT, Schuster BG, Brueckner RP, Lin E, Kaminskis A, Lasseter KC. Population pharmacokinetics and pharmacodynamics of pyridostigmine bromide for prophylaxis against nerve agents in humans. J Clin Pharmacol 1998: 38: 227–235.

    PubMed  CAS  Google Scholar 

  77. Salazar D, Much D, Nichola P, Seibold J, Shindler D, Slugg P. A pharmacokinetic-pharmacodynamic model model of d-sotalol Q-Tc prolongation during intravenous administration to healthy subjects. J Clin Pharmacol 1997: 37: 799–809.

    PubMed  CAS  Google Scholar 

  78. Anderson BJ, Holford NH, Woolard GA, Kanagasundaram S, Mahadevan M. Perioperative pharmacodynamies of acetaminophen analgesia in children. Anesthesiology 1999: 90: 411–421.

    Article  PubMed  CAS  Google Scholar 

  79. Derendorf H, Hochhaus G, Krishnaswami S, Meibohm B, Mollmann H. Optimized therapeutic ratio of inhaled corticosteroids using retrometabolism. Pharmazie. 2000 Mar;55(3):223–7.

    PubMed  CAS  Google Scholar 

  80. Lipworth BJ. The problem of dose-response and therapeutic ratio of inhaled steroids. Am J Respir Crit Care Med. 2001 Jun;163(7):1758.

    PubMed  CAS  Google Scholar 

  81. Raueneau I, Laveille C, Jochemsen R, Resplandy G, Funck-Brentano C, Jaillon P. Pharmacokineticpharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers. Clin Pharmacol Ther 1998: 64: 192–203.

    Article  Google Scholar 

  82. van den Berg BT, Derks MG, Koolen MG, Braat MC, Butter JJ, van Boxtel CJ. Pharmacokinetic/pharmacdynamic modeling of the eosinopenic and hypokalemic effects of formoterol and theophylline combination combination in healthy men. Pulm Pharmacol Ther 12: 185–192.

    Google Scholar 

  83. Belani Cp, Kearns CM, Zuhowski EG, Erkmen K, Hiponia D, Zacharski D, Engstrom C, Ramanathan RK, Caozzoli MJ, Aisner J, Egorin MJ. Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. J Clin Oncol 1999: 17: 676–684.

    PubMed  CAS  Google Scholar 

  84. Lehne G, Nordal KP, Midtvedt K, Goggin T, Brosstad F. Increased potency and decreased elimination of lamifiban, a GPIIb-IIIa antagonist, in patients with severe renal dysfunction. Thromb Haemost 1998: 79: 1119–1125.

    PubMed  CAS  Google Scholar 

  85. Mathot RA, Geus WP. Pharmacodynamic modeling of the acid inhibitory effect of ranitidine in patients in an intensive care unit during prolonged dosing: characterization of tolerance. Clin Pharmacol Ther 1999: 66: 140–151.

    PubMed  CAS  Google Scholar 

  86. Lemmens HJ, Dyck JB, Shafer SL, Stanski DR. Pharmacokinetic-pharmacodÿnamic modeling in drug development: application to the investigational opioid trefentanil. Clin Pharmacol Ther 1994: 56: 261271.

    Google Scholar 

  87. Jonsson A, Chan JC, Rydberg T, Vaaler S, Hallengren B, Cockram CS, Critchley JA, Melander A. Effects and pharmacokinetics of oral glibenclamide and glipizide in Caucasian and Chinese patients with type-2 diabetes. Eur J Clin Pharmacol. 2000 Dec;56(9–10):711–4.

    Article  PubMed  CAS  Google Scholar 

  88. US FDA Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations (Issued 10/2000, Posted 8/22/2002).

    Google Scholar 

  89. US FDA Guidance for Industry. Statistical Approaches to Establishing Bioequivalence (Issued 2/2001, Posted 2/1/2001).

    Google Scholar 

  90. US FDA Guidance for Industry. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. (Issued 8/2000, Posted 8/31/2000).

    Google Scholar 

  91. US FDA Guidance for Industry. Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations (Issued 7/2002, Posted 7/2002).

    Google Scholar 

  92. US FDA Guidance for Industry. Clozapine Tablets in Vivo Bioequivalence and in Vitro Dissolution Testing (Issued 11/15/1996, Reposted 10/15/1998).

    Google Scholar 

  93. US FDA Guidance for Industry. Phenytoin/Phenytion Sodium (capsules, tablets, suspension) In Vivo Bioequivalence and In Vitro Dissolution Testing (Issued 3/4/1994, Posted 3/2/1998).

    Google Scholar 

  94. US FDA Guidance for Industry. Potassium Chloride (slow-release tablets and capsules) In Vivo Bioequivalence and In Vitro Dissolution Testing (Revised 6/6/1994, Posted 6/22/1998).

    Google Scholar 

  95. Rohatagi S, Arya V, Zech K, Jensen BK, Barrett S. Population Pharmacokinetic/Pharmacodynamics of Ciclesonide. J.Clin. Pharmacol. 2003 (in press).

    Google Scholar 

  96. Zannikos PN, Rohatagi S, Jensen BK, DePhillips S, and Rhodes GR. Pharmacokinetics and Concentration-Effect Analysis of Intravenous RGD891, A Platelet GPIIb/IIIa Antagonist, Using Mixed Effects Modeling (NONMEM). J. Clin Pharmacol., 2000: 40: 1129–1140.

    PubMed  CAS  Google Scholar 

  97. Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. Int J Clin Pharmacol Ther. 1997 Oct;35(10):469–74. Review.

    PubMed  CAS  Google Scholar 

  98. Jackson JC. A pharmacokinetic-pharmacodynamic model of chemotherapy of human immunodeficiency virus infection that relates development of drug resistance to treatment intensity. J Pharmacokinet Biopharm 1997: 25: 713–730.

    Article  PubMed  CAS  Google Scholar 

  99. Gieschke R, Reigner BG, Steimer JL. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. hit J Clin Pharmacol Ther. 1997 Oct;35(10):469–74. Review.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Drug Metabolism and Pharmacokinetics, Aventis Pharmaceuticals, Inc., 1041 Route, Bridgewater, NJ, 202–206, USA

    Shashank Rohatagi, Nancy E. Martin & Jeffrey S. Barrett

Authors
  1. Shashank Rohatagi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Nancy E. Martin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jeffrey S. Barrett
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Aventis Pharmaceuticals, Inc., Bridgewater, New Jersey, USA

    Rajesh Krishna Ph.D., F.C.P.

Rights and permissions

Reprints and permissions

Copyright information

© 2004 Springer Science+Business Media New York

About this chapter

Cite this chapter

Rohatagi, S., Martin, N.E., Barrett, J.S. (2004). Pharmacokinetic/Pharmacodynamic Modeling in Drug Development. In: Krishna, R. (eds) Applications of Pharmacokinetic Principles in Drug Development. Springer, Boston, MA. https://doi.org/10.1007/978-1-4419-9216-1_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-9216-1_11

  • Publisher Name: Springer, Boston, MA

  • Print ISBN: 978-1-4613-4842-9

  • Online ISBN: 978-1-4419-9216-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation